Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Early ‘Scattershot’ Approach To COVID-19 Therapeutic Research Generated Little Actionable Data

Executive Summary

US FDA and NIH leaders cite lack of early clinical trial coordination as a weakness in the pandemic response that led to use of compounds that were potentially harmful and, even today, still not proven to be effective.

You may also be interested in...



Former US FDA Commish Califf Endorses ‘Tortoise’ Approach To Clinical Trials

The once and likely future FDA commissioner emphasized the value of randomized controlled trials, the fact that not all trials are good for people, and how decentralization and digitization are leaving people behind during a panel discussion. 

Robert Califf Offers ‘A Few Words In Favor Of The Tortoise’ When Conducting Clinical Trials

The once and likely future FDA commissioner emphasizes value of randomized controlled trials, the fact that not all trials are good for people, and how decentralization and digitization are leaving people behind. Takeda exec questions if industry is being bold enough.

Expanded Access With COVID Therapeutics Were ‘Worst-Case Scenario’ For Informed Consent

High-profile programs, such as convalescent plasma, also created public confusion about role of preapproval access and highlighted the importance of prospectively planning for reliable data collection, experts said at the DIA global annual meeting.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS143989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel